As a result, this pathway has become a prominent target in cancer therapy, with several small-molecule inhibitors such as Alpelisib, a PI3K inhibitor, and Capivasertib, a selective AKT inhibitor, showing promising anti-tumor efficacy in clinical studies, particularly for cancers harboring PI3K or AKT mutations (Savas et al., 2022; Turner et al., 2023). This evidence concerns the gene AKT1 and neoplasm.